The Effect of Blood Transfusion Frequency on Secretor Status Titer in Saliva and Urine Specimens of Thalassemia Patients
Abstract
Background: Thalassemia is a disease caused by a deficiency or loss of synthesis of one or more normal globin chains. In diseases that require blood transfusions, such as Transfusion Dependent Thalassemia (TDT), it is very important to examine the blood type to determine the blood to be transfused. The ABO blood type system antigen or secretor, is found in body fluids in the form of dissolved antigens, including in saliva and urine. Interference can be caused by the frequency of transfusion, which can change the secretor content in the saliva and urine of thalassemia patients, causing false negatives in the examination of secretor status. Objectives: This study aims to determine the effect of transfusion frequency on the titer of secretor status in saliva and urine specimens of Thalassemia patients. Materials and Methods: The type of study is quasi-experimental, Agglutination-Inhibition method. The research sample was 23 Thalassemia major patients. 15 patients are secretor patients, with a frequency of 1x transfusion a month were 7 people (47%), a frequency of 2x transfusion a month were 5 people (33%), and 4x transfusion a month were 3 people (20%). Results: The results of the study on Thalassemia patients obtained from saliva were titers between 1/8 to 1/256. From urine, the results were non-secretors. In contrast to previous studies, which stated that urinary is still detected but four times weaker than saliva. Based on the ANOVA statistical calculation, sig. 0.909 (p>0.05) was obtained. Conclusions: The conclusion is that there is no effect of transfusion frequency on the titer of secretor status in saliva or urine.
References
Azizah, K. N., Nurhayati, B., Marliana, N., & Durachim, A. (2023). The Effect of Saliva Collection Methods Before and After Brushing Teeth on Secretor Status Titers. Siliwangi Health Journal. 4(1), 251–259. https://doi.org/10.34011/jks.v4i1.1460
Campi C, Escovich L, Moreno A, Racca L, Racca A, Cotorruelo C, Biondi C. Expression of the gene encoding secretor type galactoside 2 α fucosyltransferase (FUT2) and ABH antigens in patients with oral lesions. Med Oral Patol Oral Cir Bucal. 2012;17:e63–68. https://doi.org/10.4317/medoral.17239
Capolongo, G., Zacchia, M., Beneduci, A., Costantini, S., Cinque, P., Spasiano, A., De Luca, G., Di Pietro, M. E., Ricchi, P., Trepiccione, F., Capasso, G., & Filosa, A. (2020). Urinary metabolic profile of patients with transfusion-dependent β-thalassemia major undergoing deferasirox therapy. Kidney and Blood Pressure Research, 45(3), 455–466. https://doi.org/10.1159/000507369
FDA, & cder. (n.d.). Highlights Of Prescribing Information. www.fda.gov/medwatch
Maharani, E. A., & Noviar, G. (2018). Medical Laboratory Technology (Mlt) Immunohematology And Blood Banking Teaching Materials (1st ed., Vol. 1). Kemenkes.
Porter, D., & Taher, J. (n.d.). 2021 Guidelines For The Management Of Transfusion Dependent Thalassaemia (TDT) Publishers Thalassaemia International Federation 4 Th Edition.
Saliba, N., Harb, A., Taher ,A., Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. J Blood Med. 2015 Jun 17;6:197–209. https://doi.org/10.2147/jbm.s72463